Canada
Patented Medicines (Notice of Compliance) Regulations
| Year of current version: | 1993 |
|---|---|
| Date of Text (Issued): | March 12, 1993 |
| Type of Text: | Implementing Rules/Regulations |
| Subject Matter: | Industrial Property, IP Regulatory Body, Patents (Inventions) |
| Notes: | |
| Available Texts: | |
| English | Patented Medicines (Notice of Compliance) Regulations |
| French | Règlement sur les médicaments brevetés(avis de conformité) |
| Related Legislation: | |
| Historical Versions: | Is superseded by |
| WIPO Lex No.: | CA027 |
![Patented Medicines (Notice of Compliance) Regulations, Complete document (pdf) [59 KB]](/shared/images/icon/new/pdf.gif){kind=icon}
![Patented Medicines (Notice of Compliance) Regulations, Complete document (html) [44 KB]](/shared/images/icon/new/html.gif){kind=icon}
Shortcuts
The notification by Canada to the WTO under Article 63.2 of TRIPS states:
The Patented Medicines (Notice of Compliance) Regulations 'allows an innovator to bring an application to prohibit the granting of marketing approval (Notice of Compliance) for a drug, that relies upon the earlier approval of a related drug until all the relevant product and use patents (but not process patents) pertaining to the earlier approved medicine have expired.'